Abbott Laboratories is launching a brand new blood check that goals to assist docs higher deal with sufferers recovering from COVID-19 by figuring out newer infections.
The North Chicago medical gadget maker’s different antibody checks purpose to point out whether or not sufferers have been uncovered to the novel coronavirus based mostly on the long-lasting infection-fighting proteins of their blood. The most recent check, which Abbott right this moment introduced was licensed for emergency use by the FDA, is designed to detect antibodies that final solely weeks to months after an infection.
“Abbott has developed checks to detect the virus at every stage of an infection, so docs and their sufferers are outfitted with information of how they’re responding to the virus and progressing by means of restoration,” CEO Robert Ford mentioned in an announcement. “Antibody checks will proceed to play an necessary position to raised perceive the virus, the prevalence of COVID-19 in an space and the place a affected person could also be of their restoration.”
Portray a extra full image of the place sufferers are of their restoration helps well being care suppliers decide if remedy, isolation or follow-up visits are wanted, the assertion says.
Abbott’s information demonstrated 99.5 % specificity (accurately producing a destructive outcome) and 95 % sensitivity (accurately producing a constructive outcome) for sufferers examined 15 days after signs began.
The brand new COVID check is Abbott’s seventh to get emergency use authorization. Different checks embrace molecular checks which can be used to detect an infection in actual time.